Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 2584-2589

  Niu, Wen Bin ^a   Gui, Shi Liang ^a   Lin, Ying Li ^b   Fu, Xing Li ^c   Ma, Jian Guo ^d   Li, Wen Ping ^d  

^a JIAMUSI UNIVERSITY   (China)

^b XUZHOU CANCER HOSPITAL   (China)

^c JIANGSU UNIVERSITY   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Biological markers; DNA methylation; Prostatic neoplasms

Indexed keywords

CADHERIN; PROTOCADHERIN 8; UNCLASSIFIED DRUG; PCDH8 PROTEIN, HUMAN;

ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; EARLY CANCER; GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; AGED; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; CADHERINS; DISEASE-FREE SURVIVAL; DNA METHYLATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS;

EID: 84924901860     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893083     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z et al: Cancer statistics, 2014. Cancer J Clin, 2014; 64(1): 11–30
2. Keane FK, Chen MH, Zhang D et al: The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer, 2014; 120(12): 1787–93
3. Chao C, Chi M, Preciado M et al: Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control, 2013; 24(9): 1615–41
4. Daniunaite K, Jarmalaite S, Kalinauskaite N et al: Prognostic Value of RASSF1 Promoter Methylation In Prostate Cancer. J Urol, 2014; S0022-5347(14)03913-5
5. Lin YL, Xie PG, Wang L et al: Aberrant methylation of protocadherin 17 and its clinical signifcance in patients with prostate cancer after radical prostatectomy. Med Sci Monit, 2014; 20: 1376–82
6. Efthimiou I, Skrepetis K, Bournia E: Single foci prostate cancer: current diagnosis and management. Curr Urol, 2013; 7(1): 1–6
7. Ragsdale JW, Halstater B, Martinez-Bianchi V: Prostate cancer screening. Prim Care, 2014; 41(2): 355–70
8. Heidenreich A, Bastian PJ, Bellmunt J et al: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol, 2014; 65(1): 124–37
9. Ling XH, Han ZD, Xia D et al: MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep, 2014; 41(5): 2779–88
10. Zhang H, Cheng S, Wang A et al: Expression of RABEX-5 and its clinical sig-nifcance in prostate cancer. J Exp Clin Cancer Res, 2014; 33: 31
11. Wang L, Xie PG, Lin YL et al: Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy. Med Sci Monit, 2014; 20: 1363–68
12. Castelli T, Cimino S, Magno C et al: Molecular markers for prostatic cancer. Front Biosci (Elite Ed), 2010; 2: 641–56
13. Park JY: Promoter hypermethylation in prostate cancer. Cancer Control, 2010; 17(4): 245–55
14. Chiam K, Ricciardelli C, Bianco-Miotto T: Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett, 2014; 342(2): 248–56
15. Van der Heijden AG: The role of methylation in urological tumours. Arch Esp Urol, 2013; 66(5): 432–39
16. Goering W, Kloth M, Schulz WA: DNA methylation changes in prostate cancer. Methods Mol Biol, 2012; 863: 47–66
17. Strehl S, Glatt K, Liu QM et al: Characterization of two novel protocadher-ins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14. Genomics, 1998; 53(1): 81–89
18. Kim SY, Yasuda S, Tanaka H et al: Non-clustered protocadherin. Cell Adh Migr, 2011; 5(2): 97–105
19. Lin YL, Wang YL, Ma JG et al: Clinical signifcance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. J Exp Clin Cancer Res, 2014; 33: 68
20. Lin YL, Ma JH, Luo XL et al: Clinical signifcance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer. J Int Med Res, 2013; 41(1): 48–54
21. Zhang D, Zhao W, Liao X et al: Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer. Oncol Rep, 2012; 28(5): 1785–91
22. He D, Zeng Q, Ren G et al: Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. Eur J Cancer Prev, 2012; 21(6): 569–75
23. Morris MR, Ricketts CJ, Gentle D et al: Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene, 2011; 30(12): 1390–401
24. Yu JS, Koujak S, Nagase S et al: PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene, 2008; 27(34): 4657–65
25. Haldrup C, Mundbjerg K, Vestergaard EM et al: DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol, 2013; 31(26): 3250–58
26. Zhang H, Qi C, Wang A et al: Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res, 2013; 32: 77
27. Stein M, Goodin S, Doyle-Lindrud S et al: Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit, 2012; 18(4): CR260–64
28. Bryniarski P, Paradysz A, Fryczkowski M: PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monit, 2011; 17(2): CR104–9